Transparency Life Sciences, LLC (TLS), the world’s first clinical-stage drug development company based on open innovation, today announced that it is applying its expertise in crowdsourcing and digital telemonitoring technology to conduct a clinical trial of Auven Therapeutics’ Kiacta™ in patients with sarcoidosis, a rare systemic inflammatory disease. Kiacta is an orally bioavailable small molecule that is…
Janssen Inc. announced it has signed an agreement, facilitated by the Johnson & Johnson Innovation center in California, with the University of Toronto’s Centre for Collaborative Drug Research (CCDR) to form an open-source collaboration focused on novel therapeutic approaches to the treatment and management of mood disorders and Alzheimer’s disease.
Horizon Pharma Announces Stockholder Approval of Its Acquisition of Vidara Therapeutics International
Horizon Pharma, Inc. (NASDAQ: HZNP) today announced that at its Special Meeting of Stockholders held today, proposals related to Horizon’s acquisition of Vidara Therapeutics International plc were approved by Horizon’s stockholders.
The parent of Millennium Pharmaceuticals said Tuesday that its top executive in Cambridge is stepping down as part of a companywide reorganization. The new structure at Takeda Pharmaceutical Co. will include a strong focus on the cancer drug business at Cambridge-based Millennium, executives said. Millennium, located near Central Square, will become the home of the…
Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer’s disease.
Baxter International Inc. and Halozyme Therapeutics, Inc., today announced that the United States Food and Drug Administration (FDA) approved Baxter’s subcutaneous treatment for adult patients with primary immunodeficiency, two years after safety concerns torpedoed their first pitch.